A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults
Latest Information Update: 27 Apr 2023
At a glance
- Drugs Semzuvolimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors United BioPharma
- 21 Apr 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 12 May 2022 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 12 May 2022 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.